SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Sunitinib Malate Capsules
Trade Name: Sutent®
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as Antineoplastic.

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1B
Specific target organ systemic toxicity (repeated exposure): Category 1
Acute aquatic toxicity: Category 1
Chronic aquatic toxicity: Category 1

EU Classification:

EU Indication of danger: Toxic to reproduction, Category 2
T - Toxic
Dangerous for the Environment

EU Risk Phrases:

R48/25 - Toxic: danger of serious damage to health by prolonged exposure if swallowed.
R61 - May cause harm to the unborn child.
R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Label Elements

Signal Word: Danger
Hazard Statements:
H360D - May damage the unborn child
H372 - Causes damage to organs through prolonged or repeated exposure
H400 - Very toxic to aquatic life
H410 - Very toxic to aquatic life with long lasting effects
Precautionary Statements:

- P201 - Obtain special instructions before use
- P202 - Do not handle until all safety precautions have been read and understood
- P281 - Use personal protective equipment as required
- P308 + P313 - IF exposed or concerned: Get medical attention/advice
- P260 - Do not breathe dust/fume/gas/mist/vapors/spray
- P264 - Wash hands thoroughly after handling
- P270 - Do not eat, drink or smoke when using this product
- P314 - Get medical attention/advice if you feel unwell
- P405 - Store locked up
- P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards

Australian Hazard Classification (NOHSC):


Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

#### Hazardous

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunitinib malate</td>
<td>341031-54-7</td>
<td>Not Listed</td>
<td>T;R48/25</td>
<td>STOT RE. 1 (H372)</td>
<td>15-40</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mannitol</td>
<td>69-65-8</td>
<td>200-711-8</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Croscarmellose sodium</td>
<td>74811-65-7</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Hard gelatin capsules</td>
<td>MIXTURE</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Povidone</td>
<td>9003-39-8</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Material Name: Sunitinib Malate Capsules
Revision date: 09-Mar-2015

Additional Information:
* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

**Eye Contact:**
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:**
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:**
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:**
Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:**
For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:**
None known

Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:**
None

5. FIRE FIGHTING MEASURES

**Extinguishing Media:**
Extinguish fires with CO2, extinguishing powder, foam, or water.

**Special Hazards Arising from the Substance or Mixture**

**Hazardous Combustion Products:**
Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:**
Not applicable

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

**Personal Precautions, Protective Equipment and Emergency Procedures**
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Environmental Precautions**
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

**Methods and Material for Containment and Cleaning Up**

**Measures for Cleaning / Collecting:**
Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Sunitinib malate
Pfizer OEL TWA-8 Hr: 10 µg/m³

Magnesium stearate
ACGIH Threshold Limit Value (TWA) 10 mg/m³
Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWAs 5 mg/m³

Exposure Controls

ingineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical State</td>
<td>Capsule</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available</td>
</tr>
<tr>
<td>Molecular Formula</td>
<td>Mixture</td>
</tr>
<tr>
<td>Solvent Solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Water Solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Color</td>
<td>Orange; opaque brown.</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>Mixture</td>
</tr>
</tbody>
</table>
9. PHYSICAL AND CHEMICAL PROPERTIES

pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Mannitol
No data available
Croscarmellose sodium
No data available
Povidone
No data available
Hard gelatin capsules
No data available
Magnesium stearate
No data available
Sunitinib malate
No data available
Decomposition Temperature (°C): No data available.
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:
Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: None known
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: May cause mild eye irritation. (based on components).
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on the hematological and reproductive systems.
Known Clinical Effects: Common adverse effects include fatigue, gastrointestinal disturbances, hematological effects, and skin effects. Other, more serious, effects include changes in liver function, liver failure
11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Mannitol
Rat  Oral  LD 50  13500 mg/kg
Mouse  Oral  LD 50  22 g/kg

Povidone
Rat  Oral  LD50  100 g/kg

Magnesium stearate
Rat  Oral  LD50 > 2000 mg/kg
Rat  Inhalation LC50 > 2000 mg/m³

Sunitinib malate
Rat  Oral  Maximally Tolerated Dose >500 mg/kg
Mouse  Oral  Maximally Tolerated Dose >500mg/kg
Dog  Oral  Maximally Tolerated Dose >500mg/kg
Non-human Primate  Oral  Maximally Tolerated Dose >1200mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sunitinib malate
Skin Irritation  Rabbit  Non-irritating
Eye Irritation  Rabbit  Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sunitinib malate
4 Week(s)  Rat  Oral  5 mg/kg/day  NOAEL  Bone marrow, Blood forming organs
28/56 Day(s)  Monkey  Oral  6.0 mg/kg/day  LOAEL  Bone Marrow, Blood forming organs
13 Week(s)  Non-human Primate  Oral  2.0 mg/kg/day  LOAEL  Bone Marrow, Blood forming organs
3 Month(s)  Rat  Oral  1.5 mg/kg/day  NOAEL  Bone Marrow, Blood forming organs
6 Month(s)  Rat  Oral  0.3 mg/kg/day  NOAEL  Bone Marrow

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Sunitinib malate
Fertility & Early Embryonic Development-Females  Rat  Oral  1.5 mg/kg/day  NOAEL  Fetotoxicity
Embryo / Fetal Development  Rabbit  Oral  0.5 mg/kg/day  NOAEL  Fetotoxicity
Embryo / Fetal Development  Rabbit  Oral  1.0 mg/kg/day  NOAEL  Maternal Toxicity
Embryo / Fetal Development  Rat  Oral  3 mg/kg/day  NOAEL  Fetotoxicity
Embryo / Fetal Development  Rat  Oral  5 mg/kg/day  NOAEL  Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sunitinib malate
Bacterial Mutagenicity (Ames)  Salmonella ,  E. coli  Negative
Mammalian Cell Mutagenicity  Negative
In Vitro Chromosome Aberration  Human Lymphocytes  Negative
11. TOXICOLOGICAL INFORMATION

Carcinogen Status:
None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Povidone
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:
Very toxic to aquatic life with long lasting effects. Releases to the environment should be avoided. See aquatic toxicity data, below:

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Sunitinib malate

\[ Daphnia magna \] (Water Flea) OECD EC50 48 Hours 3.1 mg/L
\[ Oncorhynchus mykiss \] (Rainbow Trout) OECD LC50 96 Hours 7.8 mg/L
\[ Pseudokirchneriella subcapitata \] (Green Alga) OECD EC50 72 Hours 0.32 mg/L
\[ Daphnia magna \] (Water Flea) OECD NOEC 21 Days 0.053 mg/L
\[ Ceriodaphnia dubia \] (Daphnids) EPA NOEC 7 Days 0.32 mg/L
\[ Pimephales promelas \] (Fathead Minnow) OECD NOEC 32 Days 0.00027 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Sunitinib malate

\[ Activated sludge \] OECD EC50 574 mg/L
\[ Clostridium perfringens \] FDA MIC 80 mg/L
\[ Bacillus subtilis \] (Bacterium) FDA MIC 80 mg/L
\[ Nostoc sp. \] (Freshwater Cyanobacteria) FDA MIC 5.0 mg/L

Persistence and Degradability:
No data available

Sunitinib malate
OECD Soil (various) Ready 8.8% After 28 Day(s)

Bio-accumulative Potential:
No data available

Mobility in Soil:
No data available
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

UN number: UN 3077
UN proper shipping name: Environmentally Hazardous Substance, Solid, n.o.s (sunitinib malate)
Transport hazard class(es): 9
Packing group: III
Environmental Hazard(s): Marine Pollutant

5 kg/5L Exception: Effective January 1, 2015, UN3082 and UN3077 materials contained in good quality packaging in the quantities listed below are not regulated as dangerous goods for transport by any mode:
* Single packagings containing a net quantity of 5 liters or less for liquids or a net mass of 5 kg or less for solids.
* Combination packagings containing a net quantity per inner packaging of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A

Sunitinib malate
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
EU EINECS/ELINCS List: Not Listed

Mannitol
CERCLA/SARA 313 Emission reporting: Not Listed
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material</th>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>California Proposition 65</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS)</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Croscarmellose sodium</td>
<td>Not Listed</td>
<td></td>
<td>Not Listed</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td></td>
<td>California Proposition 65</td>
<td></td>
<td>Not Listed</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Australia (AICS)</td>
<td></td>
<td>Present</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EU EINECS/ELINCS List</td>
<td></td>
<td></td>
<td></td>
<td>200-711-8</td>
</tr>
<tr>
<td>Hard gelatin capsules</td>
<td>Not Listed</td>
<td></td>
<td>Not Listed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>California Proposition 65</td>
<td></td>
<td>Not Listed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EU EINECS/ELINCS List</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>Not Listed</td>
<td></td>
<td>Not Listed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>California Proposition 65</td>
<td></td>
<td>Not Listed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
<td>Present</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Australia (AICS)</td>
<td></td>
<td>Present</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EU EINECS/ELINCS List</td>
<td></td>
<td></td>
<td></td>
<td>209-150-3</td>
</tr>
<tr>
<td>Povidone</td>
<td>Not Listed</td>
<td></td>
<td>Not Listed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>California Proposition 65</td>
<td></td>
<td>Not Listed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
<td>Present</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Australia (AICS)</td>
<td></td>
<td>Present</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EU EINECS/ELINCS List</td>
<td></td>
<td></td>
<td></td>
<td>Not Listed</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

- Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
- Specific target organ toxicity, repeated exposure-Cat.1; H373 - May cause damage to organs through prolonged or repeated exposure
- Hazardous to the aquatic environment, acute toxicity-Cat.1; H400 - Very toxic to aquatic life
- Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects

T - Toxic
N - Dangerous for the environment
Toxic to reproduction: Category 1

R61 - May cause harm to the unborn child.
R48/25 - Toxic: danger of serious damage to health by prolonged exposure if swallowed.
R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 14 - Transport Information.
Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet